Ser65
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser65  -  PKG1 (human)

Site Information
TtRAQGIsAEPQTYR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 51573802

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKG1 (human) ( 1 )
Kinases, in vitro:
PKG1 (human) ( 2 )
Treatments:
cGMP_analog ( 1 ) , DT-2 ( 1 )

Downstream Regulation
Effects of modification on PKG1:
enzymatic activity, induced ( 1 , 2 ) , ubiquitination ( 1 )

References 

1

Dey NB, et al. (2009) Cyclic GMP specifically suppresses Type-Ialpha cGMP-dependent protein kinase expression by ubiquitination. Cell Signal 21, 859-66
19168131   Curated Info

2

Busch JL, Bessay EP, Francis SH, Corbin JD (2002) A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity. J Biol Chem 277, 34048-54
12080049   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.